Display Settings:

Format

Send to:

Choose Destination
    Antimicrob Agents Chemother. 2011 Mar;55(3):1287-9. Epub 2011 Jan 3.

    Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480.

    Source

    Department of Hospital and Clinical Pharmacy, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, Netherlands. j.w.c.alffenaar@apoth.umcg.nl

    Abstract

    Susceptibility of clinical Mycobacterium tuberculosis isolates to PNU-100480 and linezolid was evaluated by the MGIT 960 system. The isolates had various susceptibilities to isoniazid (INH), rifampin, ethambutol, and streptomycin. The mean MIC for PNU-100480 was 3.2 times lower than that for linezolid. Therefore, PNU-100480 is a promising candidate to be developed further as an adjunct in the treatment of multidrug- and extensively drug-resistant tuberculosis (MDR/XDR-TB).

    PMID:
    21199931
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC3067097
    Free PMC Article

      Supplemental Content

      Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk